Author: Katrina Megget

Merck’s pain-killing arthritis drug Vioxx (rofecoxib) can still increase the risk of heart attack, stroke and death a year after patients have stopped taking the medicine, a study has found.

Abbott has announced it will repurchase $5 billion worth of the company’s shares in a bid to strengthen its stock, which has seen a 12% drop this year.

Merck Sharp & Dohme’s type 2 diabetes drug Januvia (sitagliptin) has been extended for use within NHS Scotland as a dual and triple therapy option.

Sanofi-Aventis and the Global Alliance for TB Drug Development have announced a collaboration to accelerate the discovery, development and clinical use of drugs against tuberculosis.

Johnson & Johnson has paid out more than $68 million to settle hundreds of lawsuits by women who allege they have been harmed by the company’s contraceptive patch Ortho Evra, it has been reported.